NASDAQ:EDIT - Editas Medicine Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.99 +1.54 (+7.18 %) (As of 05/22/2019 06:48 AM ET)Previous Close$21.45Today's Range$21.53 - $23.0152-Week Range$17.80 - $41.43Volume767,512 shsAverage Volume934,599 shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/ABeta2.48 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive EDIT News and Ratings via Email Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDIT Previous Symbol CUSIPN/A CIK1650664 Webhttp://www.editasmedicine.com/ Phone617-401-9000Debt Debt-to-Equity Ratio0.07 Current Ratio8.46 Quick Ratio10.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.94 million Price / Sales35.43 Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book5.21Profitability EPS (Most Recent Fiscal Year)($2.33) Net Income$-109,950,000.00 Net Margins-359.93% Return on Equity-47.64% Return on Assets-27.40%Miscellaneous Employees133 Outstanding Shares49,223,000Market Cap$1.13 billion Next Earnings Date8/5/2019 (Estimated) OptionableOptionable Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions What is Editas Medicine's stock symbol? Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT." How were Editas Medicine's earnings last quarter? Editas Medicine Inc (NASDAQ:EDIT) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The company earned $2.07 million during the quarter, compared to analyst estimates of $7.62 million. Editas Medicine had a negative return on equity of 47.64% and a negative net margin of 359.93%. The company's revenue was down 47.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.67) earnings per share. View Editas Medicine's Earnings History. When is Editas Medicine's next earnings date? Editas Medicine is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Editas Medicine. What price target have analysts set for EDIT? 9 brokerages have issued 1 year target prices for Editas Medicine's shares. Their forecasts range from $30.00 to $55.00. On average, they anticipate Editas Medicine's stock price to reach $40.25 in the next twelve months. This suggests a possible upside of 75.1% from the stock's current price. View Analyst Price Targets for Editas Medicine. What is the consensus analysts' recommendation for Editas Medicine? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Editas Medicine. Has Editas Medicine been receiving favorable news coverage? Press coverage about EDIT stock has been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Editas Medicine earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Editas Medicine's key competitors? Some companies that are related to Editas Medicine include Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Regenxbio (RGNX) and Alector (ALEC). What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), TransEnterix (TRXC), Portola Pharmaceuticals (PTLA), Alibaba Group (BABA), CA (CA), BlackRock (BLK) and Advanced Micro Devices (AMD). Who are Editas Medicine's key executives? Editas Medicine's management team includes the folowing people: Dr. Charles Albright, Chief Scientific Officer (Age 61)Ms. Cynthia L. Collins, Interim CEO & Director (Age 61)Dr. Feng Zhang, Co-Founder & Scientific Advisory Board MemberDr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member When did Editas Medicine IPO? (EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a number of of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.26%), BlackRock Inc. (7.70%), Morgan Stanley (3.81%), FMR LLC (1.58%), Nikko Asset Management Americas Inc. (1.51%) and Sumitomo Mitsui Trust Holdings Inc. (1.47%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Boris Nikolic, Charles Albright, Gerald Frank Cox, Jessica Hopfield, Katrine Bosley, Kevin Bitterman and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine. Which major investors are selling Editas Medicine stock? EDIT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, JPMorgan Chase & Co., Trexquant Investment LP, Capital Advisors Inc. OK, Fiduciary Trust Co., Crestwood Advisors Group LLC, Morgan Stanley and First Trust Advisors LP. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Charles Albright, Katrine Bosley and Vickesh Myer. View Insider Buying and Selling for Editas Medicine. Which major investors are buying Editas Medicine stock? EDIT stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Great Lakes Advisors LLC, BlackRock Inc., Renaissance Technologies LLC, Man Group plc and SHANDA ASSET MANAGEMENT HOLDINGS Ltd. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and Jessica Hopfield. View Insider Buying and Selling for Editas Medicine. How do I buy shares of Editas Medicine? Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Editas Medicine's stock price today? One share of EDIT stock can currently be purchased for approximately $22.99. How big of a company is Editas Medicine? Editas Medicine has a market capitalization of $1.13 billion and generates $31.94 million in revenue each year. The company earns $-109,950,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Editas Medicine employs 133 workers across the globe. What is Editas Medicine's official website? The official website for Editas Medicine is http://www.editasmedicine.com/. How can I contact Editas Medicine? Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected] MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 211 (Vote Outperform)Underperform Votes: 290 (Vote Underperform)Total Votes: 501MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Why do commodities matter? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.